{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:43:02Z","timestamp":1744173782946},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":84,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,9,27]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> <jats:italic>Helicobacter pylori<\/jats:italic> eradication therapies based on ranitidine bismuth citrate have recently been introduced in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To compare the efficacy of three regimens containing ranitidine bismuth citrate given for 1, 2 and 4\u2003weeks, combined with two antibiotics for the first week, in the eradication of <jats:italic>H. pylori<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Eighty\u2010six consecutive patients (50 duodenal ulcer disease, 36 non\u2010ulcer dyspepsia) with <jats:italic>H. pylori<\/jats:italic> infection were offered three eradication regimens: (a) 1\u2010week group (<jats:italic>n<\/jats:italic>=28), ranitidine bismuth citrate 400\u200amg b.d. for 7\u2003days; (b) 2\u2010week group (<jats:italic>n<\/jats:italic>=29), ranitidine bismuth citrate 400\u2003mg b.d. for 14\u2003days; and (c) 4\u2010week group (<jats:italic>n<\/jats:italic>=29), ranitidine bismuth citrate 400\u2003mg b.d. for 28\u2003days. In all patients, clarithromycin 500\u2003mg b.d. and metronidazole 500\u2003mg b.d. were given for the first week. Endoscopy was repeated 1\u2003month after the end of treatment and eradication was considered to be successful if both rapid urease test and histology were negative.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Overall, <jats:italic>H. pylori<\/jats:italic> was eradicated in 84% (72\/86) patients on intention\u2010to\u2010treat analysis, whereas the per protocol cure rate was 89% (72\/81). Eradication rates were 23\/27 (85%) (95% confidence interval (CI): 66\u201396%), 25\/27 (92%) (95% CI: 76\u201399%) and 24\/27 (89%) (95% CI: 71\u201398%) in the 1\u2010, 2\u2010 and 4\u2010week groups, respectively, on per protocol analysis, and 25\/28 (82%) (95% CI: 63\u201394%), 25\/29 (86%) (95% CI: 68\u201396%) and 24\/29 (83%) (95% CI: 64\u201394%), respectively, on intention\u2010to\u2010treat analysis (<jats:italic>P\u2003<\/jats:italic>&gt;\u20030.05, N.S.). No significant differences were observed between groups concerning duodenal ulcer healing, resolution of symptoms and adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The 1\u2010week regimen with ranitidine bismuth citrate, clarithromycin and metronidazole is effective in <jats:italic>H. pylori<\/jats:italic> eradication. Prolongation of treatment with ranitidine bismuth citrate for 2 or 4\u2003weeks does not achieve a statistically significant more favourable outcome.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01072.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:45:08Z","timestamp":1047354308000},"page":"1493-1497","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of 1\u2010week vs. 2\u2010 or 4\u2010week therapy regimens with ranitidine bismuth citrate plus two antibiotics for <i>Helicobacter pylori<\/i> eradication"],"prefix":"10.1111","volume":"15","author":[{"given":"D.","family":"Kamberoglou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Polymeros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Sanidas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Doulgeroglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Savva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Patra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Tzias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199701000-00002"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","article-title":"Helicobacter pylori in peptic ulcer disease","volume":"272","author":"NIH Consensus Conference","year":"1994","journal-title":"J Am Med Assoc"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.116287000.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(98)00218-4"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70003-5"},{"key":"e_1_2_5_7_2","first-page":"2213","article-title":"Randomized comparison of ranitidine bismuth citrate\u2010based triple therapies for Helicobacter pylori","volume":"92","author":"Laine L","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00809.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00798.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00270.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1991.tb00517.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0953-0673.1996.00241.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.2.181"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00202.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00224.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00498.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00380.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(98)00281-0"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00780.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00436.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00615.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026658215841"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00664.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00839.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00485.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01065.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.993_p.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.80252000.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00367.x"},{"key":"e_1_2_5_30_2","first-page":"A128","article-title":"Ranitidine bismuth citrate based regimens for Helicobacter pylori eradication. Which is the optimal treatment duration and antibiotics combination","volume":"47","author":"Kamberoglou D","year":"2000","journal-title":"Gut"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.00942.x"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1997.tb00052.x"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.1997.33.7.444742"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(199611)5:6<399::AID-PDS243>3.0.CO;2-4"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01072.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01072.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01072.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:26:17Z","timestamp":1695828377000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01072.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,27]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2001,9,27]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01072.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01072.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9,27]]}}}